169 related articles for article (PubMed ID: 16690468)
1. Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
Sinnott BP; Mazzone T
Endocr Pract; 2006; 12(2):183-7. PubMed ID: 16690468
[TBL] [Abstract][Full Text] [Related]
2. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
[TBL] [Abstract][Full Text] [Related]
3. Severe Combined Dyslipidemia With a Complex Genetic Basis.
Le R; Abbas M; McIntyre AD; Hegele RA
J Investig Med High Impact Case Rep; 2019; 7():2324709619877050. PubMed ID: 31538826
[No Abstract] [Full Text] [Related]
4. Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report.
Sakuma N; Iwata S; Ikeuchi R; Ichikawa T; Hibino T; Kamiya Y; Ohte N; Kawaguchi M; Kunimatsu M; Kawahara H
Metabolism; 1995 Apr; 44(4):460-5. PubMed ID: 7723668
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
[TBL] [Abstract][Full Text] [Related]
7. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
8. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.
Breslow JL; Zannis VI; SanGiacomo TR; Third JL; Tracy T; Glueck CJ
J Lipid Res; 1982 Nov; 23(8):1224-35. PubMed ID: 7175379
[TBL] [Abstract][Full Text] [Related]
9. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Nissen H; Hansen TS
Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
[TBL] [Abstract][Full Text] [Related]
10. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance.
de Villiers WJ; van der Westhuyzen DR; Coetzee GA; Henderson HE; Marais AD
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):865-72. PubMed ID: 9157949
[TBL] [Abstract][Full Text] [Related]
11. [Hyperlipoproteinemia type III with apolipoprotein E phenotype 2/2].
Engst R
Hautarzt; 1985 Nov; 36(11):629-34. PubMed ID: 4077508
[TBL] [Abstract][Full Text] [Related]
12. Unmasking of type III hyperlipoproteinemia by hypothyroidism: a dramatic illustration of altered lipoprotein metabolism in a postpartum woman.
Retnakaran R; Connelly PW; Goguen J
Endocr Pract; 2005; 11(6):394-8. PubMed ID: 16638727
[TBL] [Abstract][Full Text] [Related]
13. Dysbetalipoproteinaemia--clinical and pathophysiological features.
Blom DJ; Byrnes P; Jones S; Marais AD
S Afr Med J; 2002 Nov; 92(11):892-7. PubMed ID: 12506591
[TBL] [Abstract][Full Text] [Related]
14. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
[TBL] [Abstract][Full Text] [Related]
15. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.
Evans D; Seedorf U; Beil FU
Clin Genet; 2005 Oct; 68(4):369-72. PubMed ID: 16143024
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
19. [Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patient].
Ziemer A; Göring HD
Hautarzt; 1993 Aug; 44(8):538-44. PubMed ID: 8376110
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype.
Bea AM; Cenarro A; Marco-Bened V; Laclaustra M; Martn C; Ibarretxe D; Pint X; Arrobas T; Vials C; Civeira F; Olmos S
Clin Chem; 2023 Feb; 69(2):140-148. PubMed ID: 36644927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
